Longitudinal assessment of metabolic and neurological decline in peripheral polyneuropathy over ten years Authors: Dinara Azizkhojayeva, Gulnaz Nuskabayeva, Karlygash Sadykova, Ainur Turmanbayeva, Dana Kaldarkhan, Nurlybek Mombekov, Nigara Yerkhojayeva, Malika Raimova, Umida Yodgarova, Saodat Sobirova, Kamshat Madenbay, Ainash Oshibayeva Published: 2026 ABSTRACT AbstractAimsThis research aims to evaluate changes in metabolic status and the development of peripheral polyneuropathy (PN) in Kazakhstan.MethodsThis longitudinal observational study followed a cohort of adults with metabolic syndrome, comparing clinical, biochemical, and neurophysiological parameters between baseline (2014) and follow-up (2024). A total of 213 out of the original 570 participants were reexamined, with standardized assessments including anthropometry, blood tests, and electroneuromyography.ResultsOver the observation period, normoglycemic participants decreased from 67% to 54% while prediabetic participants increased from 17% to 37% (p < 0.001). The average BMI of participants increased from 27.8 to 29.3 kg/m2, and the prevalence of abdominal obesity rose from 72% to 85% (p < 0.001). At the 10-year follow-up, polyneuropathy was identified in 28% of participants, who totaled 60 individuals. The research found that diabetes created a nine times higher risk of PN development (OR = 9.23, p < 0.001), and BMI and waist circumference measurements also were associated with increased odds of PN at follow-up.ConclusionAdverse metabolic profiles were associated with the presence of polyneuropathy at the 10-year follow-up, including among individuals without overt diabetes. These findings highlight the importance of metabolic risk factors management to reduce the burden of PN.Keywords: Metabolic syndrome, peripheral polyneuropathy, longitudinal study, nerve conduction, electroneuromyography (ENMG), metabolic risk factors Introduction Peripheral polyneuropathy (PN) is a common chronic complication of metabolic disorders, particularly diabetes mellitus, and represents a major cause of disability and reduced quality of life worldwide. The prevalence of polyneuropathy is estimated to be 2-7% in the general population [1,2] and increases with the duration and severity of hyperglycemia. However, more recent large cohort studies have shown that prevalence estimates may vary with age and in different populations, with a prevalence of around 10% in middle-aged patients and 26–39% or greater in older populations [3]. In addition, recent studies show that neuropathic changes may occur even before overt diabetes develops [4]. For example, neuropathy has been reported in 12.1% of normoglycemic individuals with obesity and up to 40.8% of individuals with diabetes, suggesting an association between obesity and metabolic disturbances and neuropathy that is independent of glycemic control [5]. Evidence suggests that metabolic abnormalities such as obesity, dyslipidemia, insulin resistance, and hypertension contribute to peripheral nerve injury through complex mechanisms involving oxidative stress, chronic inflammation, and microvascular dysfunction. Although diabetes-related neuropathy has been extensively studied, the long-term evolution of polyneuropathy in the context of prediabetes and metabolic syndrome (MetS) remains insufficiently understood. In addition, studies examining the specific relationships between individual components of the MetS and polyneuropathy have yielded inconsistent findings [6–8]. In the study of Callaghan and colleagues, the prevalence of neuropathy among participants from a population-based cohort was graded by level of hyperglycemia. The prevalence of neuropathy was approximately 3.25% in normoglycemia, 6.29% in prediabetes and 15.12% in diabetes, indicating that metabolic factors play a major role in the development of nerve damage [9]. Moreover, many population-based studies have demonstrated that individuals with prediabetes exhibit subclinical nerve dysfunction detectable through electrodiagnosis [10–12], yet the natural progression of these abnormalities over time and their clinical correlates are still poorly defined. Furthermore, the interplay between anthropometric indicators of obesity, lipid metabolism, and glycemic control in the long-term development of polyneuropathy remains an area of active investigation. Kazakhstan and other Central Asian countries are currently experiencing a rapid epidemiological transition characterized by increasing rates of obesity, MetS, and type 2 diabetes (T2D). For example, the prevalence of T2D rose from 1,208 to 2,705 people per 100,000 population between 2014 and 2019 in Kazakhstan [13]. In individuals with T2D, peripheral neuropathy affects up to 50% of patients and represents a major contributor to disability and healthcare burden globally [14]. Despite this, there is a notable scarcity of longitudinal data assessing the long-term metabolic and neurophysiological outcomes in these populations. Understanding the early predictors and modifiable determinants of polyneuropathy is essential for designing effective prevention and intervention strategies. Therefore, this study aimed to investigate the long-term predictors and metabolic determinants of peripheral polyneuropathy over a 10-year follow-up period in a center-based cohort from Kazakhstan. Materials and methods Study design and setting This longitudinal observational study was conducted at the Clinical and Diagnostic Center of Khoja Akhmet Yassawi International Kazakh-Turkish University (Turkistan, Kazakhstan). The research investigated clinical and electrophysiological changes in peripheral polyneuropathy over ten years, examining their relationship to components of MetS. The baseline survey was conducted between 2012 and 2014 as part of the state-funded project, “Prevalence of Polyneuropathy in Patients with Metabolic Syndrome.” The baseline cohort included community-dwelling adults aged ≥25 years with varying metabolic profiles, rather than a selected high-risk population. The university polyclinic registered 570 adults who participated in the study. During the first round of the study, researchers assessed the relationship between subcutaneous fat tissue and the results of electromyoneurography. The findings of the previous study are reported elsewhere [15]. The researchers conducted a follow-up evaluation in 2024, which resulted in the successful reexamination of 213 participants from the initial study group. The researchers analyzed participants who maintained complete data for anthropometric measurements, biochemical tests, and neurophysiological assessments at both study time points. Inclusion and exclusion criteria The study included adult participants who participated in the 2012–2014 research and provided their consent to participate in the ten-year follow-up assessment. The study excluded participants who needed immediate medical care because of their acute or severe chronic decompensated conditions, including NYHA class III–IV heart failure, grade III respiratory failure, stage II–III renal or hepatic failure, psychiatric disorders, pregnancy, and ages under 18. The study excluded participants who had non-metabolic polyneuropathy conditions, including chronic inflammatory demyelinating polyneuropathy (CIDP), alcoholic neuropathy, and hereditary sensor-motor neuropathies. The cohort set-up flow diagram is presented in the previous study [15]. Anthropometric and clinical measurements The research team measured participants’ body height, weight, and waist circumference. The medical scales, with a lever-type design, measured body weight to the nearest 0.1 kg, while the stadiometer measured height without shoes or outer clothing to the nearest 1 cm. The researchers calculated body mass index (BMI) by dividing weight in kilograms by height in meters squared (kg/m2). The researchers measured waist circumference in centimeters by placing a soft tape at the midpoint between the last rib’s lower margin and the iliac crest’s upper border (which corresponds to the umbilical level). The International Diabetes Federation (IDF) defines abdominal obesity based on waist circumference measurements for Asian populations of more than 90 cm for men and more than 80 cm for women [16]. Blood pressure was measured using an automatic arm cuff after participants had been sitting for at least 5 minutes while seated. Hypertension was defined as either: systolic blood pressure more than 130 mmHg, or diastolic blood pressure exceeding 85 mmHg, or current use of prescribed medication for high blood pressure [17]. Biochemical measurements The researchers obtained venous blood samples from the antecubital vein after participants fasted for at least 12 hours. The clinical laboratory at Khoja Akhmet Yassawi International Kazakh-Turkish University performed all biochemical tests through their certified laboratory, which maintained strict quality control procedures both internally and externally. The Cobas Integra 400 analyzer from Roche Diagnostics Germany performed standard enzymatic tests to measure total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-C). The test results appeared in mmol/L format. The researchers maintained regular calibration and verification of their glucometer against biochemical analyzer results. Glycemic status was classified based on fasting plasma glucose (after at least 12 hours of fasting) and 2-hour postprandial glucose levels following a standardized meal: 150 g bread, 20 g butter, and 150 mL tea with 10 g sugar. The researchers used an Optium Xceed glucometer (MediSense, UK) to measure fasting plasma glucose (FPG) levels by collecting capillary blood through fingerpricks. The categorization of patients as normoglycemic, prediabetic, or diabetic was applied to reflect progressive stages of glucose metabolism impairment and to evaluate their relationship with polyneuropathy. Normoglycemia was defined as fasting plasma glucose <6.1 mmol/L and 2-hour postprandial glucose <7.8 mmol/L as in guideline from WHO [18]. Prediabetes was defined as FPG 6.1–6.9 mmol/L and/or 2-hour glucose 7.8–11.0 mmol/L [18]. Diabetes was defined as FPG ≥7.0 mmol/L and/or 2-hour glucose ≥11.1 mmol/L, in accordance with standard diagnostic criteria [18]. All diabetes cases in this study were classified as type 2 diabetes. Assessment of peripheral polyneuropathy Peripheral polyneuropathy was assessed using a combination of clinical, symptomatic, and electrophysiological evaluations. The Modified Neuropathy Disability Score was used as the primary clinical assessment tool. It included evaluation of ankle (Achilles) reflexes, as well as vibration, pinprick, and temperature sensation at the level of the great toe. Sensory modalities were assessed bilaterally and scored in a binary manner (0 = normal, 1 = reduced or absent). Achilles reflexes were graded as 0 (normal), 1 (present with reinforcement), or 2 (absent) [19]. The total mNDS ranged from 0 to 10 points. Neuropathy severity was classified as follows: 0–2 points (no neuropathy), 3–5 (mild), 6–8 (moderate), and 9–10 (severe). Polyneuropathy was defined as an mNDS score >2 [20] supported by neuropathic symptoms and confirmed by electrophysiological abnormalities on nerve conduction studies. Neuropathic symptoms were assessed using the Total Symptom Score, and objective nerve function was evaluated using electroneuromyography. These measures were used to support the clinical diagnosis and characterize neuropathy severity. PN was assessed only at the follow-up examination in 2024. In addition, although we have mNDS scores, variable “disability” in Table 1 refers to officially registered disability status and is not related to neuropathy-specific scoring. Table 1.Baseline demographic, anthropometric, and metabolic characteristics stratified by glycemic status. Total(n = 213)Normoglycemia(n = 142; 67%)Prediabetes (n = 35; 16%)Diabetes (n = 36; 17%)p-valueAge (years), mean (SD)42 (11)41 (11)45 (10)45 (12)0.012Sex, n (%) 0.267 Female162 (76)104 (73)31 (86)27 (77) Male51 (24)38 (27)5 (14)8 (23) Disability, n (%) 0.121 No203 (95)138 (97)33 (92)32 (91) Yes10 (5)4 (3)3 (8)3 (9) Height (cm), mean (SD)162.7 (7.6)162.9 (8.1)162.4 (6.4)162.2 (7.0)0.877Weight (kg), mean (SD)73.5 (16.1)71.9 (15.1)80.2 (16.8)72.8 (17.8)0.025Fasting glucose (mmol/L), mean (SD)5.10 (1.4)4.63 (0.7)5.96 (0.3)9.64 (2.8)<0.0012-h glucose (mmol/L), mean (SD)5.31 (1.5)5.04 (0.9)5.46 (0.8)8.12 (3.5)<0.001BMI (kg/m2), mean (SD)27.8 (5.9)27.1 (5.3)30.4 (6.1)27.8 (7.2)0.019Waist circumference (cm), mean (SD)92.7 (14.6)91.1 (14.9)98.1 (12.9)93.7 (13.9)0.015Hip circumference (cm), mean (SD)106.2 (11.3)104.6 (10.3)112.4 (12.9)106.3 (11.7)0.009Abdominal obesity, n (%) 0.021 Yes174 (82)112 (79)32 (89)30 (83) No39 (18)30 (21)4 (11)6 (17) Metabolic syndrome, n (%) 0.006 Yes50 (23)24 (17)13 (36)13 (37) No163 (77)118 (83)23 (64)22 (63) MetS components, n (%) <0.001 Without MetS163 (77)118 (83)23 (64)22 (63) MetS with normoglycemia27 (13)20 (14)2 (6)5 (14) MetS with T2DM23 (10)4 (3)11 (30)8 (23) Total cholesterol (mmol/L), mean (SD)4.94 (0.8)4.92 (0.9)4.94 (0.7)5.06 (0.8)0.183Triglycerides (mmol/L), mean (SD)1.42 (0.6)1.38 (0.5)1.53 (0.8)1.51 (0.7)0.567HDL (mmol/L), mean (SD)1.48 (0.3)1.49 (0.3)1.52 (0.3)1.44 (0.3)0.725LDL (mmol/L), mean (SD)2.79 (0.9)2.77 (0.9)2.72 (0.7)2.94 (0.8)0.215This table summarizes the baseline characteristics of study participants (n = 213) categorized into normoglycemia, prediabetes, and diabetes groups. Continuous variables are presented as mean (standard deviation), and categorical variables as number (percentage). Significant differences were observed across glycemic groups for age, weight, body mass index (BMI), waist and hip circumference, abdominal obesity, and metabolic syndrome prevalence. As expected, fasting and 2-hour glucose levels differed markedly between groups. Lipid parameters (total cholesterol, triglycerides, HDL, LDL) did not show statistically significant differences. Baseline demographic, anthropometric, and metabolic characteristics stratified by glycemic status. This table summarizes the baseline characteristics of study participants (n = 213) categorized into normoglycemia, prediabetes, and diabetes groups. Continuous variables are presented as mean (standard deviation), and categorical variables as number (percentage). Significant differences were observed across glycemic groups for age, weight, body mass index (BMI), waist and hip circumference, abdominal obesity, and metabolic syndrome prevalence. As expected, fasting and 2-hour glucose levels differed markedly between groups. Lipid parameters (total cholesterol, triglycerides, HDL, LDL) did not show statistically significant differences. Electrophysiological assessment The Neuro-EMG-Micro system from Neurosoft Ltd. in Russia was used to perform electroneuromyography (ENMG) tests and evaluate peripheral nerve conduction parameters. The testing took place while participants lay on their backs. The ENMG system measured the motor and sensory conduction velocity (NCV) and amplitude (A-wave) of the peroneal (n. peroneus), tibial (n. tibialis), and sural (n. suralis) nerves. The ENMG results enabled doctors to detect early changes in nerve function and measure the deterioration of nerve function over the ten-year study period. Follow-up and data analysis The research team conducted the same standardized assessment protocol on all available participants from the baseline cohort during the ten-year follow-up in 2024. The researchers were able to reassess 213 participants out of the initial 570 participants, as the remaining participants had either died, moved away, or become unreachable. The collected data enabled researchers to study metabolic and neurological changes over a ten-year period, identifying factors that influence the development of peripheral polyneuropathy in patients. Ethical considerations The research adhered to the ethical standards outlined in the Declaration of Helsinki (2013 revision) and received approval (Protocol №40 dated April 7, 2025) from the Local Ethics Committee at Khoja Akhmet Yassawi International Kazakh-Turkish University. All participants provided written consent before participating in the study. Statistical analysis The research team used Stata 17.0 for all statistical data analysis. The research team presented continuous data using mean values with standard deviations (SD) or median values with interquartile ranges (IQR), depending on the distribution pattern of the data. The researchers presented categorical data in the form of numbers and percentages. Independent-samples t-tests and the Mann-Whitney U test were used to analyze continuous variables, and chi-square tests or McNemar’s test were utilized to analyze categorical variables. The researchers conducted a logistic regression analysis to determine which factors predicted the development of polyneuropathy. Both univariate and multivariable models generated odds ratios (ORs) with 95% confidence intervals (CIs) for their results. The statistical significance was set at a p-value of 0.05. Results Baseline characteristics of participants A total of 213 participants were included in the analysis, with the majority classified as normoglycemic (n = 142; 67%), followed by individuals with prediabetes (n = 35; 16%) and diabetes (n = 36; 17%). The participants with prediabetes and diabetes showed older age compared to normoglycemic participants at a statistically significant level (p = 0.012). The total sample consisted of 76% female participants; however, the gender distribution across groups did not differ significantly (p = 0.267). Anthropometric and metabolic differences across glycemic groups Distinct anthropometric patterns were observed among glycemic groups (Table 1). The body weight of participants with prediabetes was 80.2 ± 16.9 kg, which was higher than that of normoglycemic (71.9 ± 15.1 kg) and diabetic (72.8 ± 17.7 kg) participants (p = 0.025). The BMI results also showed a significant difference (p = 0.019), with prediabetic participants having the highest value and normoglycemic participants having the lowest. The measurements of waist circumference and hip circumference showed identical patterns of increase from normoglycemia to diabetes (p = 0.015 and p = 0.009, respectively). The total cohort showed abdominal obesity in 82% of participants, while participants with prediabetes and diabetes had higher rates of this condition than normoglycemic participants (p = 0.021). The researchers found that glucose levels at both fasting and 2-hour post-load times increased progressively from normoglycemia to prediabetes and then to diabetes (both p < 0.001). The prevalence of metabolic syndrome reached 23% in participants, and it occurred more frequently in participants with prediabetes and diabetes than in those with normoglycemia (p = 0.006). The lipid measurements of total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol showed no significant differences between the study groups (all p > 0.05). Ten-year changes in anthropometric and metabolic indicators The participants demonstrated substantial changes in their anthropometric and metabolic measurements over the 10-year study period, as shown in Table 2. The participants experienced a statistically significant weight gain, accompanied by increases in waist and hip circumference measurements (p < 0.001 for all measurements), indicating an expansion of body dimensions and central fat accumulation. In addition, abdominal obesity prevalence rose from 82% to 93% (p < 0.001), while metabolic syndrome prevalence also increased by 7% (p = 0.001). The rise in BMI from 27.8 kg/m2 to 29.3 kg/m2 (p < 0.001) also indicates that participants developed overweight and obesity during the study period. Table 2.Longitudinal changes in anthropometric, metabolic, and glycemic characteristics over a 10-year follow-up. Year 1Year 10Changep-valueHeight (cm), mean (SD)162.7 (7.6)163.1 (7.4)↑0.101Weight (kg), mean (SD)73.5 (16.1)78.1 (1.1)↑<0.001Waist circumference (cm), mean (SD)92.7 (14.6)96.1 (14.6)↑<0.001Hip circumference (cm), mean (SD)106.2 (11.3)108.0 (11.9)↑<0.001Abdominal obesity, n (%) <0.001 Yes174 (82)198 (93)↑ No39 (18)15 (7)↓ Metabolic syndrome, n (%) 0.001 Yes50 (23)63 (30)↑ No163 (77)150 (70)↓ MetS components, n (%) 0.007 Without MetS163 (77)150 (70) MetS with normoglycemia27 (13)30 (14)↑ MetS with T2DM23 (10)33 (16)↑ BMI (kg/m2), mean (SD)27.8 (5.9)29.3 (6.1)↑<0.001Total cholesterol (mmol/L), mean (SD)4.94 (0.8)5.07 (0.9)↑0.085Triglycerides (mmol/L), mean (SD)1.42 (0.6)1.75 (1.1)↑<0.001HDL (mmol/L), mean (SD)1.48 (0.3)1.34 (0.8)↓0.009LDL (mmol/L), mean (SD)2.79 (0.9)2.81 (0.8)↑0.812Fasting glucose (mmol/L), mean (SD)5.10 (1.4)5.96 (1.7)↑<0.0012-h glucose (mmol/L), mean (SD)5.31 (1.4)6.51 (1.9)↑<0.001Glycemic status, n (%) <0.001 Normoglycemia142 (67)114 (54)↓ Prediabetes36 (17)79 (37)↑ Diabetes35 (16)20 (9)↓ This table presents changes in clinical and metabolic parameters between baseline (Year 1) and follow-up (Year 10) for the study cohort. Continuous variables are reported as mean (standard deviation), and categorical variables as number (percentage). Over the follow-up period, participants demonstrated significant increases in weight, BMI, waist and hip circumference, and prevalence of abdominal obesity and metabolic syndrome. Glycemic parameters worsened, with increases in fasting and 2-hour glucose levels and a shift from normoglycemia toward prediabetes. HDL levels decreased, while triglycerides increased significantly. Longitudinal changes in anthropometric, metabolic, and glycemic characteristics over a 10-year follow-up. This table presents changes in clinical and metabolic parameters between baseline (Year 1) and follow-up (Year 10) for the study cohort. Continuous variables are reported as mean (standard deviation), and categorical variables as number (percentage). Over the follow-up period, participants demonstrated significant increases in weight, BMI, waist and hip circumference, and prevalence of abdominal obesity and metabolic syndrome. Glycemic parameters worsened, with increases in fasting and 2-hour glucose levels and a shift from normoglycemia toward prediabetes. HDL levels decreased, while triglycerides increased significantly. The study results showed that triglyceride levels rose significantly (p < 0.001), while HDL cholesterol levels decreased substantially (p = 0.009), indicating poor lipid metabolic health (Table 2). Moreover, fasting and 2-hour glucose levels both increased substantially (p < 0.001 for both) as glucose metabolism deteriorated over the course of the study. The study results showed that participants with normoglycemia decreased from 67% to 54% while participants with prediabetes increased from 17% to 37% (p < 0.001). The diabetes prevalence among participants showed a minor decrease from 16% to 9% which could result from medical interventions. Prevalence and clinical correlates of polyneuropathy At the 10-year follow-up, polyneuropathy was identified in 28% of participants (n = 60). Anthropometric, metabolic, and glycemic characteristics of patients with and without polyneuropathy are presented in Table 3. Participants who developed polyneuropathy were older than those without the condition, with a statistically significant difference (p < 0.001). The gender distribution across groups showed no substantial difference (p = 0.195), despite women accounting for 76% of participants. Table 3.Bivariate analysis of anthropometric, metabolic, and glycemic characteristics according to the presence of peripheral polyneuropathy at 10-year follow-up. TotalPolyneuropathyp-valueNo(n = 153; 72%)Yes(n = 60; 28%)Age (years), mean (SD)52 (11)49 (10)60 (9)<0.001Sex, n (%) 0.195 Female162 (76)120 (78)42 (70) Male51 (24)33 (22)18 (30) Height (cm), mean (SD)163.1 (7.4)163.4 (7.6)162.2 (6.9)0.285Weight (kg), mean (SD)78.1 (1.1)75.9 (1.4)83.7 (1.9)0.002Waist circumference (cm), mean (SD)96.1 (1.0)93.1 (14.5)103.9 (12.1)<0.001Hip circumference (cm), mean (SD)108.0 (0.8)106.6 (12.2)111.4 (10.9)0.008Abdominal obesity, n (%)<0.001 Yes198 (93)138 (90)60 (100) No15 (7)15 (10)0 Metabolic syndrome, n (%)<0.001 Yes63 (30)33 (22)30 (50) No150 (70)120 (78)30 (50) MetS components, n (%)<0.001 Without MetS150 (70)120 (78)30 (50) MetS with normoglycemia30 (14)18 (12)12 (20) MetS with T2DM33 (16)15 (10)18 (30) BMI (kg/m2), mean (SD)29.3 (0.4)28.3 (5.9)31.8 (5.8)<0.001Total cholesterol (mmol/L), mean (SD)5.07 (0.1)4.97 (0.9)5.36 (1.0)0.006Triglycerides (mmol/L), mean (SD)1.75 (0.08)1.67 (0.9)1.92 (1.6)0.143HDL (mmol/L), mean (SD)1.34 (0.05)1.39 (0.9)1.22 (0.4)0.144LDL (mmol/L), mean (SD)2.81 (0.1)2.82 (0.8)2.79 (0.8)0.793Fasting glucose (mmol/L), mean (SD)5.96 (0.1)5.64 (1.3)6.59 (2.3)<0.0012-h glucose (mmol/L), mean (SD)6.51 (0.1)6.29 (1.8)6.94 (2.3)0.028Glycemic status, n (%) <0.001 Normoglycemia114 (54)91 (59)23 (38) Prediabetes79 (37)56 (37)23 (38) Diabetes20 (9)6 (4)14 (24) This table compares participants with and without peripheral polyneuropathy at Year 10. Continuous variables are expressed as mean (standard deviation), and categorical variables as number (percentage). Participants with polyneuropathy were significantly older and had higher body weight, BMI, waist and hip circumference, and a greater prevalence of abdominal obesity and metabolic syndrome. They also exhibited higher total cholesterol, fasting glucose, and 2-hour glucose levels. A higher proportion of individuals with diabetes was observed in the polyneuropathy group. Bivariate analysis of anthropometric, metabolic, and glycemic characteristics according to the presence of peripheral polyneuropathy at 10-year follow-up. This table compares participants with and without peripheral polyneuropathy at Year 10. Continuous variables are expressed as mean (standard deviation), and categorical variables as number (percentage). Participants with polyneuropathy were significantly older and had higher body weight, BMI, waist and hip circumference, and a greater prevalence of abdominal obesity and metabolic syndrome. They also exhibited higher total cholesterol, fasting glucose, and 2-hour glucose levels. A higher proportion of individuals with diabetes was observed in the polyneuropathy group. The research team detected significant differences in anthropometric measurements between the study groups. The participants who developed polyneuropathy displayed elevated waist and hip measurements compared to participants without neuropathy (all p < 0.01). The BMI values of participants with polyneuropathy reached significantly higher levels than those without neuropathy (31.8 ± 5.8 vs. 28.3 ± 5.9 kg/m2, p < 0.001); however, this represents an unadjusted comparison. The abdominal obesity rate reached 100% in participants with polyneuropathy, whereas it was 81% in participants without neuropathy at a statistically significant level (p < 0.001). The study results showed that participants with polyneuropathy experienced more frequent metabolic problems (p < 0.001). The study results showed that total cholesterol levels were higher in participants with polyneuropathy (5.36 ± 1.0 mmol/L vs. 4.97 ± 0.9 mmol/L, p = 0.006), but triglycerides and HDL and LDL cholesterol levels remained unchanged between groups. The study results showed that participants with neuropathy had elevated fasting and 2-hour postprandial glucose levels compared to other participants (p < 0.001 and p = 0.028, respectively). In addition, participants with polyneuropathy had lower normoglycemia rates (38% vs. 59%) and higher diabetes rates (24% vs. 6%). Baseline anthropometric and metabolic characteristics were also analyzed in relation to polyneuropathy at follow-up, with results presented in Supplementary Table S1. This analysis was largely consistent with findings at Year 10 (Table 3). In both analyses, age, measures of central and general adiposity (waist circumference, BMI), and glycemic parameters were higher in participants with polyneuropathy. Baseline differences in anthropometric measures and fasting glucose were already evident, indicating that these factors were present prior to the assessment of neuropathy. Neurophysiological findings The results of this study showed that participants who received a clinical polyneuropathy diagnosis presented with severe neurophysiological deficits than those without the condition (Table 4). The Total Symptom Score and Neuropathy Disability Score showed significant increases in participants who had polyneuropathy (p < 0.001 for both). The TSS values were 3.89 in neuropathic patients but only 0.57 in non-neuropathic participants, while the mNDS values were 2.56 in neuropathic patients but only 0.08 in non-neuropathic participants. Table 4.Bivariate analysis of neuropathy scores and nerve conduction parameters according to the presence of peripheral polyneuropathy. TotalPolyneuropathyp-valueNo(n = 153; 72%)Yes(n = 60; 28%)TSS1.51 (2.2)0.57 (1.2)3.89 (2.3)<0.001mNDS0.78 (1.5)0.08 (0.4)2.56 (1.8)<0.001 Motor neurons Amplitude (mV), mean (SD) N. medianus7.52 (2.4)7.75 (2.4)6.94 (2.5)0.031 N. ulnaris8.12 (2.3)8.35 (2.2)7.53 (2.3)0.017 N. peroneus3.44 (1.7)3.55 (1.7)3.15 (1.5)0.114 N. tibialis9.29 (4.3)9.61 (4.4)8.46 (3.9)0.079 Nerve conduction velocity (m/s), mean (SD) N. medianus53.6 (8.4)55.1 (7.9)49.7 (8.6)<0.001 N. ulnaris53.9 (10.2)54.1 (10.5)53.2 (9.4)0.528 N. peroneus45.4 (8.1)46.6 (7.5)42.2 (8.7)<0.001 N. tibialis48.2 (7.2)49.2 (6.3)45.5 (8.5)<0.001 Sensory neurons Amplitude (mV), mean (SD) N. medianus15.4 (9.4)16.2 (9.1)13.1 (9.9)0.028 N. suralis10.4 (6.8)10.3 (6.7)10.8 (6.9)0.581 Nerve conduction velocity (m/s), mean (SD) N. medianus56.9 (11.9)59.3 (9.8)50.7 (14.5)<0.001 N. suralis53.2 (15.1)55.6 (13.2)47.4 (17.9)<0.001This table presents comparisons of clinical neuropathy scores and electroneuromyography (ENMG) parameters between participants with and without polyneuropathy at Year 10. Patients with polyneuropathy demonstrated significantly higher Total Symptom Score (TSS) and modified Neuropathy Disability Score (mNDS), indicating greater clinical severity. Neurophysiological assessment showed reduced motor amplitudes (median and ulnar nerves) and slower nerve conduction velocities in both motor (median, peroneal, tibial nerves) and sensory (median and sural nerves) fibers among affected individuals. Bivariate analysis of neuropathy scores and nerve conduction parameters according to the presence of peripheral polyneuropathy. This table presents comparisons of clinical neuropathy scores and electroneuromyography (ENMG) parameters between participants with and without polyneuropathy at Year 10. Patients with polyneuropathy demonstrated significantly higher Total Symptom Score (TSS) and modified Neuropathy Disability Score (mNDS), indicating greater clinical severity. Neurophysiological assessment showed reduced motor amplitudes (median and ulnar nerves) and slower nerve conduction velocities in both motor (median, peroneal, tibial nerves) and sensory (median and sural nerves) fibers among affected individuals. Amplitude of the compound motor action potential (CMAP) and nerve conduction velocities decreased significantly in participants who developed polyneuropathy. The amplitudes of the median and ulnar nerves showed significant decreases in neuropathic patients at 6.94 ± 2.5 mV and 7.53 ± 2.3 mV, respectively, compared with 7.75 ± 2.4 mV and 8.35 ± 2.2 mV in non-neuropathic participants (p = 0.031 and p = 0.017, respectively). The amplitudes of the peroneal and tibial nerves showed a downward trend but did not reach statistical significance. The median sensory nerve amplitude measurements were lower in participants with neuropathy compared to those without neuropathy (p = 0.028). Regarding motor nerve conduction velocity measurements, participants who developed neuropathy showed significant decreases in multiple nerves. Motor nerve conduction velocity measurements of the median, peroneal, and tibial nerves were significantly slower in participants with neuropathy compared to those without (all p < 0.001). The ulnar NCV measurements showed no significant decrease (p = 0.528). The median and sural sensory NCV measurements showed substantial reductions in participants with polyneuropathy (p < 0.001 for both), which supported the presence of widespread peripheral nerve conduction slowing. Predictors of polyneuropathy The odds ratios and corresponding p-values from unadjusted and multivariable-adjusted logistic regression models are presented in Figure 1 to evaluate the determinants of polyneuropathy. The presence of polyneuropathy increased with age (OR = 1.12, p < 0.001). It was associated with waist circumference, hip circumference, and BMI (OR = 1.10, p < 0.001), suggesting that central and total body fat may play a role in the development of polyneuropathy. Heatmap of unadjusted and adjusted logistic regression models for predictors of polyneuropathy presence. The figure presents the associations between clinical, metabolic, and neurophysiological variables and the presence of peripheral polyneuropathy. Two models are shown: an unadjusted model (left column) and a multivariable-adjusted model (right column). Odds ratios (OR) with corresponding p-values are displayed for each variable. Note: Covariates of the multivariate model adjusted for: age, weight, waist and hip circumferences, AO, MetS, BMI, total cholesterol, fasting glucose, 2-hour glucose, glycemic status. The results of this study showed that diabetes patients developed polyneuropathy at a significantly higher rate than normoglycemic participants (OR = 9.23, p < 0.001), although prediabetes showed no significant association (Figure 1). Analysis of potential confounders through multivariable adjustment revealed that most variables lost statistical significance because age, obesity, and metabolic disturbances shared common pathways (Figure 1). Age (ORadj = 1.10, p < 0.001) and waist circumference (ORadj = 1.08, p = 0.015) remained independent risk factor for polyneuropathy. The characteristics that were not included in the adjusted model were excluded either due to lack of statistical significance or failure to meet model fit criteria, as presented in Supplementary Table S2. Discussion This longitudinal observational cohort study examines the development of peripheral polyneuropathy associated with metabolic disorders in Kazakhstan over a ten-year period. The participants in the study had normal blood sugar levels and were predominantly women, exhibiting extensive abdominal fat distribution. However, they demonstrated substantial weight accumulation together with deteriorating blood sugar management and rising rates of metabolic syndrome during the observation period. According to data for 2024, polyneuropathy affected 28% of participants, who demonstrated elevated BMI levels and central obesity and deteriorated blood sugar management. The neurophysiological tests revealed extensive damage to motor and sensory nerves in participants who developed polyneuropathy. The NTS and TSS proved to be one of the most significant factors related to neuropathy development after researchers controlled for age, obesity, and metabolic conditions. The research findings show that metabolic disorders can lead to long-term nerve damage. The combination of high blood sugar, abnormal fat levels, and excess body fat creates excessive reactive oxygen species, which exceed the body’s antioxidant defenses. The excessive metabolic load causes damage to neuronal mitochondria while disrupting axonal transport and leading to structural deterioration of peripheral nerves [21]. The development of endothelial dysfunction leads to impaired blood flow to nerves. The combination of insulin resistance and elevated free fatty acids decreases nitric oxide availability [22], leading to blood vessel constriction and a reduction in oxygen supply to nerve cells. In addition, research conducted in Turkey [23,24], Bulgaria [25], and the USA [26] has shown that patients with impaired glucose tolerance develop early nerve conduction problems, supporting the theory that nerve damage begins during the early stages of blood sugar irregularities. Current research used a longitudinal design to show that metabolic deterioration leads to neuropathic symptoms and signs, which previous cross-sectional studies failed to establish through inconsistent results. The results of this study showed that participants with abdominal obesity, metabolic syndrome, and high BMI tend to have higher odds of polyneuropathy. The biological mechanism underlying this relationship is an ongoing low-level inflammation present in obesity and metabolic syndrome conditions, which accelerates the progression of nerve damage. The presence of TNF-α, IL-6, and CRP cytokines from adipose tissue disrupts Schwann cell function while increasing tissue damage from oxidation and making pain signals more sensitive [27,28]. Inflammatory conditions in the body trigger tissue scarring and alter the interaction between immune cells and neurons, creating a prolonged toxic environment for neurons [21]. The combination of these processes creates a feedback loop that begins with metabolic problems, leading to blood vessel damage and inflammation that ultimately causes permanent nerve tissue degeneration. The study confirms previous research by showing that obesity measurements, including BMI, hip, and waist circumferences, directly link to neuropathy development. For example, a study from Indonesia using the Toronto clinical scoring system showed that a higher waist-to-hip ratio is significantly associated with more severe diabetic polyneuropathy [29]. The accumulation of fat tissue in the body leads to widespread inflammation and damage to small blood vessels, which disrupts the normal functioning of peripheral nerves. The research findings reveal no direct link between triglycerides and cholesterol levels and the development of neuropathy in this study population, despite international studies yielding conflicting results [30–32]. Comparison of baseline characteristics with findings at 10-year follow-up showed some differences. Lipid parameters demonstrated weaker and less consistent associations at baseline, whereas total cholesterol reached statistical significance at follow-up. Similarly, glycemic status categories were not significantly different at baseline but were more strongly associated with polyneuropathy at follow-up, possibly reflecting changes in metabolic profiles over time. These findings may suggest that higher adiposity and impaired glycemic control are associated with polyneuropathy [31], while baseline differences may reflect early characteristics rather than established correlates observed at follow-up. The study confirms that the risk of neuropathy increases with age, as neurons become more susceptible to damage with age. The combination of declining nerve repair abilities, rising metabolic stress, and vascular changes makes people more prone to developing polyneuropathy as they age [33,34]. The results show that age remains a significant risk factor for neuropathy after researchers controlled for other characteristics, demonstrating its fundamental role in the development of the condition. The research results indicate that nerve function deteriorates due to decreased signal strength and slower transmission rates in motor and sensory pathways, suggesting a combination of nerve damage and insulation breakdown. The observed nerve damage patterns match those found in large-scale research projects, including the Rochester Diabetic Neuropathy Study, which indicates that metabolic nerve damage follows identical patterns across different populations [35]. The decreased signal strength indicates that fewer functioning nerve fibers are present for impulse transmission [36]. The slowed conduction speed suggests damage to the myelin sheath [37], which usually facilitates rapid signal transmission. The observed dual pattern of nerve damage aligns with the characteristics of polyneuropathy. The electrophysiological patterns from our study align with those found in diabetic neuropathy research [38,39]; however, our results indicate that these changes occur in patients with various metabolic conditions, extending beyond diabetes. Strengths and limitations of the study The research contains multiple essential advantages. The study stands as one of the few population-based longitudinal investigations in Central Asia that examines the development of peripheral polyneuropathy over time while monitoring metabolic risk factors. The 10-year follow-up design enables researchers to study how conditions change over time, rather than making inferences from single-point measurements. The research combines clinical evaluations with biochemical tests and electrophysiological assessments to achieve a complete neuropathy assessment that surpasses the methods used in previous studies. The research employs standardized diagnostic techniques to evaluate metabolic conditions and nerve function, which enables better comparison with international research findings. The research addresses a critical knowledge gap on polyneuropathy in Kazakhstan. However, several limitations should be noted. The study faces its primary challenge because 357 participants out of 570 failed to return for follow-up evaluation, which creates selection bias and reduces the study’s applicability to other populations. The study population consisted mainly of women, which makes it challenging to identify sex-related differences in neuropathy development. The study lacks measurements of HbA1c, fasting insulin, inflammatory markers, and insulin resistance indices, which could have provided more insight into the disease mechanisms. The research failed to measure lifestyle elements, including diet, smoking, physical activity, and alcohol consumption, because these factors affect both metabolic health and nerve function. The research was conducted at a single location and focused on adults aged 25 and above, which limits its applicability to younger people or diverse ethnic groups. Conclusion The research conducted in Kazakhstan represents the first longitudinal study to track the development of peripheral polyneuropathy over ten years through the assessment of metabolic risk factors in community residents. The research revealed that obesity rates, prevalence of metabolic syndrome, and glucose regulation issues increased significantly during the study period. The research established that neuropathy development over time depends most heavily on three factors, which include age, obesity, and blood sugar control problems. The research results demonstrate the requirement for early detection of metabolic disorders and specific treatment approaches to stop neuropathy development before patients develop overt diabetes. The success of public health initiatives that focus on obesity prevention and lifestyle changes will determine the rate at which neuropathy advances in populations at high risk. Supplementary Material supplementary tables.docx Funding Statement This research was funded by the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan (Grant No. BR24992814). Author contribution Conceptualization, D.A. and G.N.; methodology, G.N. and A.T.; validation, K.S.; formal analysis, N.M.; investigation, N.Y. and M.R.; resources, G.N.; data curation, D.K.; writing – original draft preparation, D.A.; writing – review and editing, G.N., K.M. and A.O.; visualization, U.Y. and S.S; supervision, G.N.; securing funding: A.O. and G.N. All authors have read and agreed to the published version of the manuscript. Disclosure statement The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Ethics statement The research adhered to the ethical standards outlined in the Declaration of Helsinki (2013 revision) and received approval (Protocol №40 dated April 7, 2025) from the Local Ethics Committee at Khoja Akhmet Yassawi International Kazakh-Turkish University. All participants provided written consent before participating in the study. Data availability statement The data that support the findings of this study are available on request from the corresponding author, AO. The data are not publicly available due to privacy reasons. References: Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers. Associated Data Supplementary Materials supplementary tables.docx Data Availability Statement The data that support the findings of this study are available on request from the corresponding author, AO. The data are not publicly available due to privacy reasons.